Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Sales and Divestitures (2023 - 2025)

Compass Therapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 104.38% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 104.38%, while the annual FY2025 figure was $1.1 million, 104.38% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.1 million at Compass Therapeutics, up from $823000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.1 million in Q4 2025 and bottomed at $122000.0 in Q2 2023.
  • The 3-year median for Gains from Sales and Divestitures is $412500.0 (2023), against an average of $516400.0.
  • The largest annual shift saw Gains from Sales and Divestitures surged 75.0% in 2024 before it surged 265.78% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $300000.0 in 2023, then soared by 75.0% to $525000.0 in 2024, then skyrocketed by 104.38% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Gains from Sales and Divestitures are $1.1 million (Q4 2025), $823000.0 (Q3 2025), and $823000.0 (Q2 2025).